Gliosarcoma Clinical Trial
Official title:
Pilot Study to Evaluate the Safety, Tolerability and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma (Phase I)
Verified date | April 2023 |
Source | Center Trials & Treatment Europe |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this pilot study is to determine the safety, tolerability, and the maximum tolerated dose intranasal administration of temozolomide (TMZ) as a single agent in Treatment on the patients with GBM. Intranasal administration is a new method of treating brain tumours for the direct administration of drugs, inhibitors or viruses, with minimal involvement of the BBB. The investigators know the orally prescribed standard chemotherapy temozolomide (TMZ) is widely used to treat glioma tumours. Received evidence of safety and efficacy in a full cycle of preclinical trials (on GLP Standart) and tests of calculated doses of intranasal administration of TMZ in healthy volunteers. Intranasal administration of temozolomide is considered as GBM therapy, which provides direct access to a therapeutic dose of the drug into the brain (to the neoplastic process) with low toxicity
Status | Completed |
Enrollment | 30 |
Est. completion date | October 28, 2022 |
Est. primary completion date | September 21, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 70 Years |
Eligibility | Inclusion Criteria: - Informed consent signed - 21 years or older - Histologically confirmed the diagnosis of Grade 4 astrocytic tumour, which includes glioblastoma, giant cell glioblastoma, gliosarcoma, and glioblastoma with oligodendroglial components - The availability of histological material for the possibility of revising histological verification - IDH 1 Mutation and IDH2 Mutation are not taken into account when enrolling in that study - MGMT promoter methylation MUST BE CONFIRMED - Must have a Karnofsky performance status of = 70% and the ability to use intranasal administration - Sexually active fertile subjects (male and female) must agree to use accepted methods of contraception during the course of the study and for 3 months after the last intranasal administration of Temozolomide - Female subjects of childbearing potential must have a negative pregnancy test at screening. - Must be capable of understanding and complying with the protocol requirements Exclusion Criteria: - History of hypersensitivity to TMZ or any of its excipients - The subject has had major surgery within 28 days prior to starting study treatment, or had non-water-tight dural closure during previous surgery, or has unhealed wounds from previous surgery - The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding. - The subject is pregnant or breastfeeding - The subject suffered a stroke according to the results of the first MRI upon admission - Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible. Subjects must have fully recovered from the effects of prior chemotherapy (haematological and bone marrow suppression effects), generally at least 3 weeks from the most recent administration (6 weeks for nitrosoureas). Subjects may not have received more than 1 cycle of Irinotecan and Temozolomide as previous relapse therapy - Subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee |
Country | Name | City | State |
---|---|---|---|
Bosnia and Herzegovina | Central Contact | Banja Luka | |
Bulgaria | Central Contact | Plovdiv, | |
Georgia | Central Contact | Tbilisi |
Lead Sponsor | Collaborator |
---|---|
Center Trials & Treatment Europe |
Bosnia and Herzegovina, Bulgaria, Georgia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Percentage of Participants Alive 6 Months After Start of Treatment of Temozolomide for intranasal administration | Overall survival (OS) will be determined as the time in days from the start of treatment ( randomizations day ) to death due to any cause was estimated by the Kaplan-Meier method.
If it was not known for certain that the participant to die, time will be censored at the last date the participant with GBM or Gliosarcomawas known to be alive, date of magnetic resonance imaging (MRI), etc, - assessment, which will be defined as the latest among the date of the last visit. |
180 days | |
Other | The effectiveness of intranasal administration of modified Temozolomide | The effectiveness of the intranasal administration of modified Temozolomide will be evaluated by four MRIs with perfusion (first MRI performed one day before randomization day). The results of all MRI in dynamics will be appreciated by a consultation of radiologists. | up to 90 days (or withdrawal of consent or another discontinuation criterion) from date of randomization | |
Primary | The randomized study to determine the safety of Intranasal Administration of modified Temozolomide. | Incidence of Treatment-Emergent Adverse Events will be estimated by the number of participants with Glioblastoma or Gliosarcoma according to the NCI CTC (5.0) with adverse events (AE) in all cohorts. | up to 60 days (or withdrawal of consent or another discontinuation criterion) from date of randomization | |
Secondary | The maximum tolerated therapeutic dose (MTD) of modified Temozolomide for intranasal administration | In the present study, the maximum dose of modified Temozolomide for intranasal administration is 200 mg / M2 a single daily intranasal administration in a course of 5 days. The frequency of adverse events, unacceptable toxicity, or haematological reactions is estimated on a scale the NCI CTCAE (v. 5.0) | up to 90 days (or withdrawal of consent or another discontinuation criterion) from date of randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
Completed |
NCT02386826 -
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT01227434 -
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT00995007 -
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
|
Phase 2 | |
Completed |
NCT00960492 -
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
|
Phase 1 | |
Completed |
NCT00525525 -
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
|
Phase 2 | |
Completed |
NCT00402116 -
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00165477 -
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 2 | |
Recruiting |
NCT04555577 -
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
|
Phase 1 | |
Active, not recruiting |
NCT03137888 -
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
|
Phase 2 | |
Suspended |
NCT03197506 -
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
|
Phase 2 | |
Active, not recruiting |
NCT01430351 -
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
|
Phase 1 | |
Active, not recruiting |
NCT04396860 -
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
|
Phase 2/Phase 3 | |
Completed |
NCT00879437 -
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
|
Phase 2 | |
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Recruiting |
NCT04528680 -
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT01837862 -
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
|
Phase 1/Phase 2 | |
Completed |
NCT02502708 -
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
|
Phase 1 | |
Completed |
NCT00612651 -
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
|
Phase 1 |